<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327754</url>
  </required_header>
  <id_info>
    <org_study_id>FY1004</org_study_id>
    <nct_id>NCT02327754</nct_id>
  </id_info>
  <brief_title>Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout</brief_title>
  <acronym>UPWARD</acronym>
  <official_title>Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa Kagaku Kenkyusho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanwa Kagaku Kenkyusho Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of topiroxostat on urinary albumin
      excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia
      with or without gout. Participants are randomized to placebo (n=20) or topiroxostat (n=40)
      for 28 weeks. The investigational drugs for this study are supplied by FUJI YAKUHIN CO., LTD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urine albumin creatinine ratio</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sUA, eGFR, L-FABP, HbA1c, SBP, DBP, TC</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topiroxostat, (Oral daily dosing for 28 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, (Oral daily dosing for 28 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiroxostat BID, (Oral daily dosing for 28 weeks)</intervention_name>
    <description>The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.</description>
    <arm_group_label>Active comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BID, (Oral daily dosing for 28 weeks)</intervention_name>
    <description>Subjects randomized to the placebo arm will receive placebo.</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes patients

          -  Clinically or pathologically diagnosed diabetic nephropathy

          -  Hyperuricemic or gout patients

          -  Estimated glomerular filtration rate (eGFR) &gt;= 30 mL/min/1.73m^2 and urine albumin
             creatinine ratio (UACR) greater than or equal to 45 and less than 300 mg/g

        Exclusion Criteria:

          -  Patient has known non-diabetic nephropathy (other than nephrosclerosis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanwa Kagaku Kenkyusho Co., Ltd.</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>461-8631</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

